Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecentriq in NSCLC with brain metastasis
NCT03526900Phase 2Completed
- Sponsor
- Fundación GECP
- Start
- Jul 2018
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Started Jul 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03526900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03526900.